Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

Author(s):

Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.

EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond

EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

Now Viewing

EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

EP: 6.Streamlining Transitions Between Academic and Community Centers

EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

Video content above is prompted by the following:

What are the primary barriers preventing widespread use of bispecific antibody therapies in community practices, and what innovative solutions or models of care could help address these challenges?
Several ASH 2024 abstracts highlighted community center experiences with bispecific antibody therapies. What insights from these studies stand out to you, and how can they guide broader adoption of these therapies in the community setting?